These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
461 related articles for article (PubMed ID: 31843356)
1. [Potential application of fibroblast growth factor 23-klotho axis in chronic kidney disease]. Lacroix JS; Urena-Torres P Nephrol Ther; 2020 Mar; 16(2):83-92. PubMed ID: 31843356 [TBL] [Abstract][Full Text] [Related]
2. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study. Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324 [TBL] [Abstract][Full Text] [Related]
3. Klotho/FGF23 Axis in Chronic Kidney Disease and Cardiovascular Disease. Lu X; Hu MC Kidney Dis (Basel); 2017 Jul; 3(1):15-23. PubMed ID: 28785560 [TBL] [Abstract][Full Text] [Related]
4. [Effect of Ronghuang Granule on serum FGF23, FGFRs and Klotho in non-dialysis patients with CKD-MBD and kidney deficiency and damp-heat syndrome]. Hu S; Wang D; Zhang R; Cao Y; Jin H; Mao Y; Wei L; Ren K; Zhang X; Wang Y Nan Fang Yi Ke Da Xue Xue Bao; 2018 Dec; 38(12):1427-1432. PubMed ID: 30613009 [TBL] [Abstract][Full Text] [Related]
5. FGF23 and Klotho in chronic kidney disease. Olauson H; Larsson TE Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):397-404. PubMed ID: 23666415 [TBL] [Abstract][Full Text] [Related]
7. [Correlations of FGF23 and Klotho with cardiovascular injury in chronic kidney disease patients]. Gan L; Zhou Q Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Sep; 42(9):1058-1065. PubMed ID: 28989152 [TBL] [Abstract][Full Text] [Related]
8. Association between FGF23, α-Klotho, and Cardiac Abnormalities among Patients with Various Chronic Kidney Disease Stages. Tanaka S; Fujita S; Kizawa S; Morita H; Ishizaka N PLoS One; 2016; 11(7):e0156860. PubMed ID: 27400031 [TBL] [Abstract][Full Text] [Related]
9. FGF23 and klotho at the intersection of kidney and cardiovascular disease. Edmonston D; Grabner A; Wolf M Nat Rev Cardiol; 2024 Jan; 21(1):11-24. PubMed ID: 37443358 [TBL] [Abstract][Full Text] [Related]
10. Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. Shimamura Y; Hamada K; Inoue K; Ogata K; Ishihara M; Kagawa T; Inoue M; Fujimoto S; Ikebe M; Yuasa K; Yamanaka S; Sugiura T; Terada Y Clin Exp Nephrol; 2012 Oct; 16(5):722-9. PubMed ID: 22457086 [TBL] [Abstract][Full Text] [Related]
11. Klotho and endocrine fibroblast growth factors: markers of chronic kidney disease progression and cardiovascular complications? Kuro-O M Nephrol Dial Transplant; 2019 Jan; 34(1):15-21. PubMed ID: 29800324 [TBL] [Abstract][Full Text] [Related]
12. Plasmatic Klotho and FGF23 Levels as Biomarkers of CKD-Associated Cardiac Disease in Type 2 Diabetic Patients. Silva AP; Mendes F; Carias E; Gonçalves RB; Fragoso A; Dias C; Tavares N; Café HM; Santos N; Rato F; Leão Neves P; Almeida E Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30934737 [TBL] [Abstract][Full Text] [Related]
13. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis. Koizumi M; Komaba H; Fukagawa M Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554 [TBL] [Abstract][Full Text] [Related]
14. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study. Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826 [TBL] [Abstract][Full Text] [Related]
15. Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients. Lin HH; Liou HH; Wu MS; Lin CY; Huang CC Nephrology (Carlton); 2014 Nov; 19(11):672-8. PubMed ID: 25113414 [TBL] [Abstract][Full Text] [Related]
16. Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate. Xie J; Yoon J; An SW; Kuro-o M; Huang CL J Am Soc Nephrol; 2015 May; 26(5):1150-60. PubMed ID: 25475745 [TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease. Wan M; Smith C; Shah V; Gullet A; Wells D; Rees L; Shroff R Nephrol Dial Transplant; 2013 Jan; 28(1):153-61. PubMed ID: 23180879 [TBL] [Abstract][Full Text] [Related]
18. New insights into the FGF23-Klotho axis. Olauson H; Vervloet MG; Cozzolino M; Massy ZA; Ureña Torres P; Larsson TE Semin Nephrol; 2014 Nov; 34(6):586-97. PubMed ID: 25498378 [TBL] [Abstract][Full Text] [Related]
19. Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD. Liabeuf S; Ryckelynck JP; El Esper N; Ureña P; Combe C; Dussol B; Fouque D; Vanhille P; Frimat L; Thervet E; Mentaverri R; Prié D; Choukroun G; Clin J Am Soc Nephrol; 2017 Dec; 12(12):1930-1940. PubMed ID: 29074818 [TBL] [Abstract][Full Text] [Related]
20. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease]. Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]